Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mika Pietila"'
Autor:
Hussein Al‐Akhrass, Mika Pietilä, Johanna Lilja, Ella‐Maria Vesilahti, Johanna M. Anttila, Heidi M. Haikala, Pauliina M. Munne, Juha Klefström, Emilia Peuhu, Johanna Ivaska
Publikováno v:
Molecular Oncology, Vol 16, Iss 1, Pp 116-129 (2022)
In breast cancer, the currently approved anti‐receptor tyrosine‐protein kinase erbB‐2 (HER2) therapies do not fully meet the expected clinical goals due to therapy resistance. Identifying alternative HER2‐related therapeutic targets could off
Externí odkaz:
https://doaj.org/article/3226b21a139d4cb2aecf7f1e1b37a9ec
Autor:
Mika Pietilä, Pranshu Sahgal, Emilia Peuhu, Niklas Z. Jäntti, Ilkka Paatero, Elisa Närvä, Hussein Al-Akhrass, Johanna Lilja, Maria Georgiadou, Olav M. Andersen, Artur Padzik, Harri Sihto, Heikki Joensuu, Matias Blomqvist, Irena Saarinen, Peter J. Boström, Pekka Taimen, Johanna Ivaska
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
The EGF receptor HER2 is an oncogene protein thought to reside at the plasma membrane, but its endosomal trafficking is currently unclear. Here, the authors report that HER2 is endocytosed and that sortillin-related receptor 1 (SORLA) promotes endoso
Externí odkaz:
https://doaj.org/article/b28b871b1d0643feb58c297bc60c61de
Autor:
Mika Pietilä, Siri Lehtonen, Elina Tuovinen, Kaarina Lähteenmäki, Saara Laitinen, Hannu-Ville Leskelä, Antti Nätynki, Juha Pesälä, Katrina Nordström, Petri Lehenkari
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31671 (2012)
Human mesenchymal stem cells (hMSCs) display immunosuppressive properties in vitro and the potential has also been transferred successfully to clinical trials for treatment of autoimmune diseases. OX-2 (CD200), a member of the immunoglobulin superfam
Externí odkaz:
https://doaj.org/article/ad08aae4cac149c496e2f344c16298e0
Autor:
Geraldine Vidhya Vijay, Na Zhao, Petra Den Hollander, Mike J. Toneff, Robiya Joseph, Mika Pietila, Joseph H. Taube, Tapasree R. Sarkar, Esmeralda Ramirez-Pena, Steven J. Werden, Maryam Shariati, Ruli Gao, Mary Sobieski, Clifford C. Stephan, Nathalie Sphyris, Noayuki Miura, Peter Davies, Jeffrey T. Chang, Rama Soundararajan, Jeffrey M. Rosen, Sendurai A. Mani
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-14 (2019)
Abstract Background Triple-negative breast cancers (TNBCs), which lack receptors for estrogen, progesterone, and amplification of epidermal growth factor receptor 2, are highly aggressive. Consequently, patients diagnosed with TNBCs have reduced over
Externí odkaz:
https://doaj.org/article/94966eb44ff14ce28f1cf950c225b5fb
Autor:
Nick A. Kuburich, Petra den Hollander, Maria Castaneda, Mika Pietilä, Ximing Tang, Harsh Batra, Francisco Martínez-Peña, Tanvi H. Visal, Tieling Zhou, Breanna R. Demestichas, Ritesh V. Dontula, Jojo Y. Liu, Joanna Joyce Maddela, Reethi S. Padmanabhan, Lan Thi Hanh Phi, Matthew J. Rosolen, Thiru Sabapathy, Dhiraj Kumar, Filippo G. Giancotti, Luke L. Lairson, Maria Gabriela Raso, Rama Soundararajan, Sendurai A. Mani
Publikováno v:
Cell Reports, Vol 42, Iss 12, Pp 113470- (2023)
Summary: Epithelial-mesenchymal transition (EMT) empowers epithelial cells with mesenchymal and stem-like attributes, facilitating metastasis, a leading cause of cancer-related mortality. Hybrid epithelial-mesenchymal (E/M) cells, retaining both epit
Externí odkaz:
https://doaj.org/article/253d5b2d577048579918e7d5d14d75ec
Autor:
Elisa Närvä, Maria E. Taskinen, Sergio Lilla, Aleksi Isomursu, Mika Pietilä, Jere Weltner, Jorma Isola, Harri Sihto, Heikki Joensuu, Sara Zanivan, Jim Norman, Johanna Ivaska
Publikováno v:
iScience, Vol 25, Iss 6, Pp 104459- (2022)
Summary: MASTL is a mitotic accelerator with an emerging role in breast cancer progression. However, the mechanisms behind its oncogenicity remain largely unknown. Here, we identify a previously unknown role and eminent expression of MASTL in stem ce
Externí odkaz:
https://doaj.org/article/49fc6d2d2b354fafb82f10b872696eca